Gastric Carcinoma Clinical Trial
Official title:
A Cohort Study on Prediction of Metastasis of Gastric Carcinoma by DNA Methylation Biomarkers
Gastric carcinoma (GC) is the second leading cause of cancer death throughout the world. In previous multi-center study, we have found that the prevalence of GDNF family receptor alpha 1(GFRA1), serum response factor (SRF), and ZNF382 methylation alterations were inversely and coordinately associated with GC metastasis and the patients' overall survival throughout discovery and testing cohorts in China, Japan and Korea. The present cohort study is to investigate whether methylation of those genes can predict the metastasis and prognosis of GC.
Background: Metastasis is the leading cause of death for gastric carcinoma (GC). Currently,
GC prognosis is primarily determined based on the clinical data and pathological stages of
patients at the time of diagnosis and treatment. However, successful management of GC
patients is still hampered by lack of highly sensitive and specific biomarkers capable of
predicting prognosis and likelihood of metastasis. GFRA1 hypomethylation along with SRF and
ZNF382 hypermethylation were found to be potential synergistic biomarkers for the prediction
of GC metastasis in our previous multi-center study. In addition, p16 and E-cadherin were
also correlated with GC metastasis in Chinese cohort. To investigate the predictive value of
those genes' methylation on metastasis potential in GC, we carried out the prospective cohort
study.
Methods: 198 early stage GC patients without lymph node or distal metastasis were included in
the present study. Baseline information of E-cadherin, GFRA1, p16, SRF and ZNF382 methylation
status of the GC from 191 cases was obtained by MethyLight. The follow-up examination was
carried out in a double-blind study with a 6-month interval. The association between gene
methylation and metastasis of GC was analyzed with SPSS16.0 software. All P-values were
two-sided.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04602026 -
The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer
|
N/A | |
| Not yet recruiting |
NCT03599778 -
XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT00256321 -
Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
| Recruiting |
NCT02617134 -
CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02317471 -
Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03735511 -
A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
|
||
| Recruiting |
NCT04410302 -
Patient-Derived Xenografts to Reduce Cancer Health Disparities
|
||
| Recruiting |
NCT05596188 -
Anxiety Before Non-cardiac Surgery in Adults
|
||
| Recruiting |
NCT02611024 -
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT04254107 -
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT01348009 -
Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00639522 -
Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma
|
Phase 1 | |
| Recruiting |
NCT05811546 -
Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma
|
||
| Recruiting |
NCT05229809 -
Clinical Trial of Yiqi Wenyang Jiedu Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Gastric Cancer
|
Phase 4 | |
| Recruiting |
NCT02409199 -
A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT00970138 -
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06408220 -
Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer
|
N/A | |
| Recruiting |
NCT04443036 -
Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma
|
N/A | |
| Active, not recruiting |
NCT04505553 -
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
|
Phase 2 |